Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24

Benzinga · 16h ago
Morgan Stanley analyst Jeffrey Hung maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $28 to $24.